TSTickerStarGet alerts

DataMeds AI launches up to $7,045,403 at-the-market common stock offering

DataMeds AI, Inc. entered into an at-the-market sales agreement with Dawson James Securities, Inc. to offer and sell from time to time up to $7,045,403 of common stock. Assuming sales at the November 16, 2026 closing price of $0.642 per share, the program could issue up to 10,974,147 shares and raise shares outstanding from 5,724,857 to up to 16,699,004, with net proceeds intended for debt repayment, working capital and other general corporate purposes.

Share this story

Key takeaways

  • Offering size: The prospectus supplement covers an at-the-market offering of common stock with an aggregate offering price of up to $7,045,403.

  • Sales agent: Dawson James Securities, Inc. will act as sales agent or principal and will receive a 3.0% cash commission on aggregate gross proceeds, with certain expenses reimbursable.

  • Potential share issuance: At the assumed $0.642 per share price, up to 10,974,147 shares may be sold, taking shares outstanding from 5,724,857 to up to 16,699,004.

  • Use of proceeds: Net proceeds, if any, are intended for debt repayment, working capital and other general corporate purposes, with pending proceeds invested in short-term, investment-grade instruments and government securities.

  • Dilution: On a fully subscribed basis at $0.642 per share, pro forma as adjusted net tangible book value would be $(22.7) million, or $(1.36) per share, with immediate dilution of $2.00 per share to new investors.

  • No minimum offering: The number of shares sold, gross proceeds, commissions and net proceeds are not determinable because no minimum offering amount is required, and either party may terminate the Sales Agreement on ten days' prior notice.

  • Other dilution sources: Share counts exclude 9,442,355 warrant shares with a weighted average exercise price of $7.31, 21,687,403 shares issuable on conversion of outstanding convertible promissory notes, and 920,191 shares reserved under the Amended and Restated 2023 Equity Incentive Plan.

Key metrics

Maximum ATM offering sizeAs of November 17, 2026
$7,045,403 aggregate offering price
Maximum shares issuable under the offeringAssuming sales at $0.642 per share
Up to 10,974,147 shares
Common stock outstanding immediately prior to offeringNovember 16, 2026
5,724,857 shares
Common stock outstanding immediately after offeringImmediately after offering, assuming full $7,045,403 sale at $0.642
Up to 16,699,004 shares
Assumed offering priceNovember 16, 2026 closing price on The Nasdaq Capital Market
$0.642 per share
Sales agent commission
3.0% of aggregate gross proceeds
Sales agent expense reimbursement
Legal counsel fees and expenses up to a maximum of $75,000, plus such legal counsel costs, fees and expenses not to exceed $10,000 per fiscal year upon request
Public floatAs of November 17, 2026
$21,136,211

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

Follow MEDS in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert